New Protein Target May Boost Cancer Drug Efficacy
A laboratory study shows that targeting the DKC1 protein could help make certain resistant tumors vulnerable to PARP inhibitors.
Updated on Oct. 31, 2026 in Cancer
Live Poll
Do you believe new research on synthetic lethality will improve cancer treatment outcomes for more patients?
Researchers have identified that depleting the protein dyskerin (DKC1) sensitizes HR-proficient cancer cells to PARP inhibitors in laboratory models. This discovery could eventually broaden the use of PARP inhibitor therapies to solid tumors that currently do not respond to this class of medication.
Why it matters
PARP inhibitors are currently limited to treating BRCA-mutated tumors, leaving many patients with HR-proficient solid tumors without this treatment option. This study offers a potential new mechanism to overcome that resistance and expand the therapeutic scope of existing drugs.
A preclinical study using a CRISPR-Cas9 screen and xenograft models demonstrated that depleting the DKC1 protein sensitizes HR-proficient cancer cells to PARP inhibitors. These findings are preliminary and have not yet been tested in human subjects.
The details
The study found that DKC1 is essential for the pseudouridylation of chromatin-associated RNAs, a process that helps maintain genome stability. When DKC1 is depleted, it triggers chromatin remodeling that mimics the cellular state of homologous recombination (HR) deficiency. This state compromises the recruitment of vital repair proteins like BRCA1 and RAD21, making the cancer cells vulnerable to PARP inhibitors, which disrupt DNA repair.
Timeline
The research findings were published on October 31, 2026.
Health Landscape
The standard of care for PARP inhibitors is currently limited by the prevalence of HR-proficient tumors that do not respond to these drugs. This research represents an effort to overcome this widespread resistance by identifying new biological targets that mimic genetic vulnerabilities.
This development is in early-stage laboratory research and does not currently change how cancer is diagnosed or treated in clinical practice. Patients with questions about the role of genetic testing or PARP inhibitors in their specific care plan should discuss these topics with their oncologist.
The takeaway
This discovery identifies a new potential pathway to make currently resistant tumors susceptible to existing cancer treatments. Discuss the implications of genetic tumor profiling with your oncology team to understand which therapies might be appropriate for your specific diagnosis.
Further reading
For more on the latest research in this field, explore our Cancer section.
More information
View the original peer-reviewed research article for full details on this study.
Source note: This article includes information reported by Nature.
Live Poll
Do you believe new research on synthetic lethality will improve cancer treatment outcomes for more patients?
